IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

John P. Cooke et al.

Title:

ENHANCEMENT OF VASCULAR FUNCTION BY MODULATION

OF ENDOGENOUS NITRIC OXIDE PRODUCTION OR ACTIVITY

Appl. No.:

10/618,835

Filing Date: 07/15/2003

Examiner:

J. Russel

Art Unit:

1654

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR § 1.97(b)**

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Under 37 CFR §§ 1.56 and 1.97(b), Applicants bring to the Examiner's attention the documents on the attached SB/08. This information Disclosure Statement is being filed before the mailing date of a first Office action on the merits for the above-referenced application.

Copies of the listed documents are attached and submitted with the European Search Report of 02-05-2004, (7 pages) on which they were cited. The European application claims priority to U.S. Application no. 08/556,035, filed 11-09-1995, now U.S. Pat. No. 5,891,459 and U.S. Application no. 08/695,792, filed 08-12-1996, issued as U.S. Pat. No. 5,852,058.

The '035 application is part of this family, as shown by the underlined portion of the family chain, which is reproduced here: This application is a continuation of application no. 10/060,252, filed 02-01-2002, now US Pat. No. 6,646,006, which application is a continuation of application no. 09/930,833, filed 08-15-2001, now U.S. Pat. No. 6,642,208, which application is a continuation of application no. 09/075,509, filed 05-08-1998, now U.S. Pat. no. 6,337,321, which application is a continuation of application no. 08/556,035, filed

11-09-1995, now U.S. Pat. No. 5,891,459, which application is a continuation-in-part of application no. 08/336,159, filed 11-08-1994, now abandoned, which application is a continuation-in-part of application no. 08/076,312, filed 06-11-1993, now U.S. Pat. No. 5,428,070.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is hereby authorized to charge any fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or to credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

SEAN A, PASSIND Stephen B. Maebius

Attorney for Applicant

Registration No. 35,264

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: Facsimile:

(202) 672-5569

(202) 672-5399

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

nu<u>mber.</u>

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Date Submitted: April 9, 2004

(use as many sheets as necessary)
Sheet 1 of 1

Complete if Known	70	6	
10/618,835	7	31	
07/15/2003	APR	0 9 2004	
John P. Cooke	2	3	
1654	12	O. Car	
J. Russel	V.	PART	
080618-0237	/	TAUE	
	10/618,835 07/15/2003 John P. Cooke 1654 J. Russel	Complete if Known 10/618,835 07/15/2003 John P. Cooke 1654 J. Russel	

U.S. PATENT DOCUMENTS						
Examiner Cite Initials* No.		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
		Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
	D1	5,372,807		POIANI et al.	12-13-1994	
	D2	5,278,189		RATH et al.	01-11-1994	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Тө
	D3	WO 88/01872	Dudrick Medical Research	03-24-1988		
	D4	EP 0 483 614 A	NB Int'l. Technologies	05-06-1992		
	D5	WO 94/16729 A	Neorx Corporation	08-04-1994		
	D6	GB 953,997	AEC Chim. Organ. Biolog.	04-02-1964		
	D7	EP 0 546 796 A1	Ajinomoto Co., Inc.	06-16-1993		
	D8	WO 94/28721 A	Univ. Leland Stanford Jr.	12-22-1994		
	D9	GB 1,304,499	Tixier, Madeleine	01-24-1973		

	NON PATENT LITERATURE DOCUMENTS	_
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
D10	RIBEIRO, ALDA, et al., "Arginine-Lysine Combination in Immunodepressed Elderly Patients, Long-Term Controlled Trial," <i>Clinical Trials Journal</i> 1986, United Kingdom, vol. 23, no. 3, pp. 185-192.	
D11	IGNARRO, LOUIS J., et al., "Basic Polyamino Acids Rich in Arginine, Lysine, or Ornithine Cause Both Enhancement of and Refractoriness to Formation of Endothelium-Derived Nitric Oxide in Pulmonary Artery and Vein," <i>Circulation Research</i> , vol. 64, no. 2, 1989, pages 315-329.	
	·	
	No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. D10 RIBEIRO, ALDA, et al., "Arginine-Lysine Combination in Immunodepressed Elderly Patients, Long-Term Controlled Trial," <i>Clinical Trials Journal</i> 1986, United Kingdom, vol. 23, no. 3, pp. 185-192. D11 IGNARRO, LOUIS J., et al., "Basic Polyamino Acids Rich in Arginine, Lysine, or Ornithine Cause Both Enhancement of and Refractoriness to Formation of Endothelium-Derived Nitric Oxide in Pulmonary

1181056		
Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.